Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α

Patent metadata

Field	Value
Publication number	US-11897951-B2
Application number	US-202117553916-A
Country	US
Kind code	B2
Filing date	Dec 17, 2021
Priority date	Dec 18, 2020
Publication date	Feb 13, 2024
Grant date	Feb 13, 2024

Abstract

The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory and/or autoimmune disease, and specifically rheumatoid arthritis. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF-α and at least two ISVDs bind to IL-6. The present disclosure also provides nucleic acids, vectors and compositions.

First claim

The invention claimed is:

1. A polypeptide, or a composition comprising the polypeptide, wherein the polypeptide comprises at least three immunoglobulin single variable domains (ISVDs), wherein each of said ISVDs comprises three complementarity determining regions (CDR1 to CDR3, respectively), optionally linked via one or more peptidic linkers; and wherein:
a) a first ISVD binds to IL-6 and comprises
i. a CDR1 which has the amino acid sequence of SEQ ID NO: 6;
ii. a CDR2 which has the amino acid sequence of SEQ ID NO: 10 amino acid difference(s) with SEQ ID NO: 10; and
iii. a CDR3 which has the amino acid sequence of SEQ ID NO: 14;

b) a second ISVD binds to IL-6 and comprises;
iv. a CDR1 which has the amino acid sequence of SEQ ID NO: 8
v. a CDR2 which has the amino acid sequence of SEQ ID NO: 12 amino acid difference(s) with SEQ ID NO: 12; and
vi. a CDR3 which has the amino acid sequence of SEQ ID NO: 16; and

c) a third ISVD binds to TNF-α and comprises
vii. a CDR1 which has the amino acid sequence of SEQ ID NO: 9;
viii. a CDR2 which has the amino acid sequence of SEQ ID NO: 13 amino acid difference(s) with SEQ ID NO: 13; and

ix. a CDR3 which has the amino acid sequence of SEQ ID NO: 17.

2. The polypeptide or composition according to claim 1 , which is a pharmaceutical composition which further comprises at least one pharmaceutically acceptable carrier, diluent or excipient and/or adjuvant, and optionally comprises one or more further polypeptides and/or compounds.

3. The polypeptide or composition according to claim 1 , wherein the polypeptide consists of three ISVDs, wherein:
a) said first ISVD comprises a CDR1 having the amino acid sequence of SEQ ID NO:6, a CDR2 having the amino acid sequence of SEQ ID NO: 10 and a CDR3 having the amino acid sequence of SEQ ID NO: 14;
b) said second ISVD comprises a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO: 12 and a CDR3 having the amino acid sequence of SEQ ID NO: 16; and
c) said third ISVD comprises a CDR1 having the amino acid sequence of SEQ ID NO:9, a CDR2 having the amino acid sequence of SEQ ID NO: 13 and a CDR3 having the amino acid sequence of SEQ ID NO: 17.

4. The polypeptide or composition according to claim 1 , wherein:
a) the amino acid sequence of said first ISVD has a sequence identity of more than 90% with SEQ ID NO: 2;
b) the amino acid sequence of said second ISVD has a sequence identity of more than 90% with SEQ ID NO: 4; and
c) the amino acid sequence of said third ISVD has a sequence identity of more than 90% identity with SEQ ID NO: 5.

5. The polypeptide or composition according to claim 1 , wherein:
a)said first ISVD has the amino acid sequence of SEQ ID NO: 2;
b) said second ISVD has the amino acid sequence of SEQ ID NO: 4; and
c) said third ISVD has the amino acid sequence of SEQ ID NO: 5.

6. The polypeptide or composition according to claim 1 , wherein said polypeptide further comprises one or more other groups, residues, moieties or binding units, optionally linked via one or more peptidic linkers, in which said one or more other groups, residues, moieties or binding units provide the polypeptide with increased half-life, compared to the corresponding polypeptide without said one or more other groups, residues, moieties or binding units.

7. The polypeptide or composition according to claim 6 , in which said one or more other groups, residues, moieties or binding units that provide the polypeptide with increased half-life is chosen from the group consisting of binding units that can bind to serum albumin or and binding units that can bind to a serum immunoglobulin.

8. The polypeptide or composition according to claim 7 , wherein the binding units that can bind to serum albumin are binding units that can bind to human serum albumin.

9. The polypeptide or composition according to claim 7 , wherein the binding units that can bind to a serum immunoglobulin are binding units that can bind to IgG.

10. The polypeptide or composition according to claim 7 , in which said binding unit that provides the polypeptide with increased half-life is an ISVD that can bind to human serum albumin.

11. The polypeptide or composition according to claim 10 , wherein the ISVD binding to human serum albumin comprises
i. a CDR1 which has the amino acid sequence of SEQ ID NO: 7 amino;
ii. a CDR2 which has the amino acid sequence of SEQ ID NO: 11; and
iii. a CDR3 which has the amino acid sequence of SEQ ID NO: 15.

12. The polypeptide or composition according to claim 11 , wherein the amino acid sequence of said ISVD binding to human serum albumin has a sequence identity of more than 90% with SEQ ID NO: 3.

13. The polypeptide or composition according to claim 1 , wherein the polypeptide comprises or consists of an amino acid sequence having a sequence identity of more than 90% with SEQ ID NO: 1.

14. A nucleic acid comprising a nucleotide sequence that encodes a polypeptide according to claim 1 .

15. A non-human host or host cell comprising a nucleic acid according to claim 14 .

16. A method for producing a polypeptide, said method at least comprising the steps of:
a) expressing a nucleic acid according to claim 14 ; optionally followed by:
b) isolating and/or purifying the polypeptide.

17. A method of treating an inflammatory and/or autoimmune disease, wherein said method comprises administering, to a subject in need thereof, an effective amount of a polypeptide according to claim 1 .

18. The method according to claim 17 , wherein the inflammatory and/or autoimmune disease is rheumatoid arthritis.

Assignees

• Ablynx Nv
• Sanofi Sa

Inventors

• Rommelaere Heidi
• Asbrand Christian
• Biesemann Nadine
• Brigé Ann
• Cornelis Sigrid
• Heyninck Karen
• Lorent Eric
• Van Zwam Shanna

Classifications

• C07K16/248 Primary

  IL-6 · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• C07K16/2875

  against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241) · CPC title

• C07K2317/31

  multispecific · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title